Home›Articles›Subcutaneous versus intravenous amivantamab in the PALOMA-3 trialArticleSubcutaneous versus intravenous amivantamab in the PALOMA-3 trialArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnAmivantamab/hyaluronidase, Drugs and Medicinal Substances Well-attested SourcesAmivantamab/hyaluronidase (Wikipedia)History: PALOMA-3Quote, History: PALOMA-3The incidence of systemic ARRs of any grade was 13% for subcutaneous amivantamab compared to 66% IRRs for intravenous amivantamab.View the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.